Technology
Health
Medical
Soleno Therapeutics
$2.359876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.30 (14.63%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell SLNO and other stocks, options, ETFs, and crypto commission-free!
About
Soleno Therapeutics, Inc. Common Stock, also called Soleno Therapeutics, is a healthcare company, focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Read More It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Employees
23
Headquarters
Redwood City, California
Founded
1999
Market Cap
65.10M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
443.90K
High Today
$2.55
Low Today
$2.11
Open Price
$2.19
Volume
1.03M
52 Week High
$5.07
52 Week Low
$1.11
Collections
Technology
Health
Medical
Therapy
Healthcare
2014 IPO
US
North America
News
Simply Wall St17h
Did Changing Sentiment Drive Soleno Therapeutics’s (NASDAQ:SLNO) Share Price Down A Worrying 68%?
Soleno Therapeutics, Inc. (NASDAQ:SLNO) shareholders are doubtless heartened to see the share price bounce 52% in just one week. But that doesn’t change the fact that the returns over the last three years have been disappointing. In that time, the share price dropped 68%. So it’s good to see it climbing back up. The rise has some hopeful, but turnarounds are often precarious. View our latest analysis for Soleno Therapeutics Soleno Therapeutics didn’t have any revenue in the last year, so it’s fair to say ...
InvestorPlaceMar 15
Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today
Soleno Therapeutics (NASDAQ: SLNO ) had a Friday to remember as the biopharmaceutical company made some headway in a successful clinical trial of a treatment for a genetic disorder.
Price Paid on Robinhood
23% Lower
Right Now
52 Week Low
$1.11
Average Price Paid
$3.07
52 Week High
$5.07
Earnings
-$0.36
-$0.23
-$0.11
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
$0.02 per share